HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Biomarker Data and Patient Preference Inform Perioperative Therapy Selection in Early HER2+ Breast Cancer

December 13th 2023

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.

T-DXd Continues to Show Robust CNS Activity in HER2+ Breast Cancer With Brain Metastases

December 13th 2023

Javier Cortés, MD, PhD, expands on the importance of investigating the central nervous system activity of trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases; key efficacy data from the pooled analysis of the agent in the DESTINY-Breast01, -02 and -03 trials; and more.

Zanidatamab Triplet Shows Positive PFS Outcomes in HR+/HER2+ Metastatic Breast Cancer

December 8th 2023

Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

Atezolizumab Plus Neoadjuvant HP/Chemo Does Not Significantly Improve pCR in HER2+ Breast Cancer

December 8th 2023

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

PFS Benefit Observed With Tucatinib Plus T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer

December 6th 2023

The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.

BDC-1001 Plus Pertuzumab Is Under Exploration in HER2+ Breast Cancer

December 6th 2023

The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.

EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

November 28th 2023

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.

Dr Mamounas on Surgical De-Escalation Strategies in HER2+ Breast Cancers

November 15th 2023

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Demonstrates Real-World Intracranial Efficacy in Metastatic HER2+ Breast Cancer

November 14th 2023

Data from a real-world study in Japan showed that fam-trastuzumab deruxtecan-nxki displayed intracranial efficacy in patients with HER2-positive breast cancer harboring brain metastases and/or leptomeningeal carcinomatosis.

Frontline Pyrotinib Plus Trastuzumab and Docetaxel Improves PFS in HER2+ Metastatic Breast Cancer

November 8th 2023

The addition of pyrotinib to trastuzumab and docetaxel led to a significant improvement in progression-free survival compared with placebo plus trastuzumab and docetaxel in patients with newly diagnosed, HER2-positive metastatic breast cancer.

Neoadjuvant Inetetamab Combo Shows Efficacy, Tolerability in Locally Advanced HER2+ Breast Cancer

November 8th 2023

The combination of inetetamab, pertuzumab, paclitaxel, and carboplatin elicited responses with an acceptable safety profile when administered as neoadjuvant treatment in patients with locally advanced HER2-positive breast cancer.

Trastuzumab Duocarmazine Provides Numerical OS Benefit in Pretreated HER2+ Breast Cancer

November 7th 2023

Treatment with vic-trastuzumab duocarmazine demonstrated a trend toward numerically prolonged overall survival compared with physician’s choice of treatment in patients with pretreated HER2-positive metastatic breast cancer.

Trastuzumab Deruxtecan Sustains Survival Benefits in HER2-Low Metastatic Breast Cancer

October 21st 2023

Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.

Retrospective Analysis Shows Trastuzumab Deruxtecan Improves Intracranial Responses in HER2+ Breast Cancer

October 21st 2023

Fam-trastuzumab deruxtecan-nxki elicited higher rates of intracranial responses vs comparator therapies in patients with HER2-positive metastatic breast cancer with both stable and active brain metastases.

De-Escalation of Therapy Remains a Focus for Early-Stage HER2+ Breast Cancer

October 17th 2023

Francisco Javier Esteva, MD, PhD, discusses the management of early-stage HER2-positive breast cancer with a focus on de-escalation strategies, emphasizes the ongoing efforts to de-escalate chemotherapy without compromising effective treatments, and expands on the ongoing debate regarding the role of carboplatin in this setting.

Experience Helps Guide ILD Prevention/Management With Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 17th 2023

Sneha Phadke, DO, MPH, expands on the investigation of trastuzumab deruxtecan as a possible treatment option for patients with HER2-positive breast cancer who have high-risk residual disease following neoadjuvant systemic therapy.

Trastuzumab Deruxtecan Continues to Reshape HER2+ Breast Cancer Treatment Paradigm

October 17th 2023

Lubna Chaudhary, MD, MS, discusses how findings from the various DESTINY-Breast trials affected the treatment landscape in HER2-positive breast cancer, the trials’ impact on the treatment arena, the evolving treatment landscape for patients with HER2-positive breast cancer, and the importance of staying updated on new drugs and clinical trials.

Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer

September 29th 2023

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.

Trastuzumab Biosimilar Receives CHMP Recommendation for HER2+ Breast and Gastric Cancer

September 18th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization of EirGenix’s biosimilar for trastuzumab for the treatment of patients with HER2-positive breast and metastatic gastric cancers.

Dr Quiroga on the Emergence of HER2-Low in Breast Cancer

September 1st 2023

Dionisia Quiroga, DO, PhD, discusses the emergence of the HER2-low categorization in breast cancer as well as current treatment options for patients with HER2-low disease.